Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia

Hiroyoshi Takeuchi, Cynthia Siu, Gary Remington, Gagan Fervaha, Robert B. Zipursky, George Foussias, Ofer Agid

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Although some studies have suggested that relapse may be associated with antipsychotic treatment resistance in schizophrenia, the number and quality of studies is limited. The current analysis included patients with a diagnosis of first-episode schizophrenia or schizoaffective disorder who met the following criteria: (1) referral to the First-Episode Psychosis Program between 2003 and 2013; (2) treatment with an oral second-generation antipsychotic according to a standardized treatment algorithm; (3) positive symptom remission; (4) subsequent relapse (i.e., second episode) in association with non-adherence; and (5) reintroduction of antipsychotic treatment with the same agent used to achieve response in the first episode. The following outcomes were used as an index of antipsychotic treatment response: changes in the brief psychiatric rating scale (BPRS) total and positive symptom scores and number of patients who achieved positive symptom remission and 20 and 50% response. A total of 130 patients were included in the analyses. Although all patients took the same antipsychotic in both episodes, there were significant episode-by-time interactions for all outcomes of antipsychotic treatment response over 1 year in favor of the first episode compared to the second episode (50% response rate: 48.7 vs. 10.4% at week 7; 88.2 vs. 27.8% at week 27, respectively). Although antipsychotic doses in the second episode were significantly higher than those in the first episode, results remained unchanged after adjusting for antipsychotic dose. The present findings suggest that antipsychotic treatment response is reduced or delayed in the face of relapse following effective treatment of the first episode of schizophrenia.

Original languageEnglish
JournalNeuropsychopharmacology
DOIs
Publication statusAccepted/In press - 2018 Jan 1

Fingerprint

Antipsychotic Agents
Schizophrenia
Recurrence
Therapeutics
Psychotic Disorders
Brief Psychiatric Rating Scale
Referral and Consultation

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. / Takeuchi, Hiroyoshi; Siu, Cynthia; Remington, Gary; Fervaha, Gagan; Zipursky, Robert B.; Foussias, George; Agid, Ofer.

In: Neuropsychopharmacology, 01.01.2018.

Research output: Contribution to journalArticle

Takeuchi, Hiroyoshi ; Siu, Cynthia ; Remington, Gary ; Fervaha, Gagan ; Zipursky, Robert B. ; Foussias, George ; Agid, Ofer. / Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. In: Neuropsychopharmacology. 2018.
@article{41c38b859eed4092a544b35d0dc21b15,
title = "Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia",
abstract = "Although some studies have suggested that relapse may be associated with antipsychotic treatment resistance in schizophrenia, the number and quality of studies is limited. The current analysis included patients with a diagnosis of first-episode schizophrenia or schizoaffective disorder who met the following criteria: (1) referral to the First-Episode Psychosis Program between 2003 and 2013; (2) treatment with an oral second-generation antipsychotic according to a standardized treatment algorithm; (3) positive symptom remission; (4) subsequent relapse (i.e., second episode) in association with non-adherence; and (5) reintroduction of antipsychotic treatment with the same agent used to achieve response in the first episode. The following outcomes were used as an index of antipsychotic treatment response: changes in the brief psychiatric rating scale (BPRS) total and positive symptom scores and number of patients who achieved positive symptom remission and 20 and 50{\%} response. A total of 130 patients were included in the analyses. Although all patients took the same antipsychotic in both episodes, there were significant episode-by-time interactions for all outcomes of antipsychotic treatment response over 1 year in favor of the first episode compared to the second episode (50{\%} response rate: 48.7 vs. 10.4{\%} at week 7; 88.2 vs. 27.8{\%} at week 27, respectively). Although antipsychotic doses in the second episode were significantly higher than those in the first episode, results remained unchanged after adjusting for antipsychotic dose. The present findings suggest that antipsychotic treatment response is reduced or delayed in the face of relapse following effective treatment of the first episode of schizophrenia.",
author = "Hiroyoshi Takeuchi and Cynthia Siu and Gary Remington and Gagan Fervaha and Zipursky, {Robert B.} and George Foussias and Ofer Agid",
year = "2018",
month = "1",
day = "1",
doi = "10.1038/s41386-018-0278-3",
language = "English",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia

AU - Takeuchi, Hiroyoshi

AU - Siu, Cynthia

AU - Remington, Gary

AU - Fervaha, Gagan

AU - Zipursky, Robert B.

AU - Foussias, George

AU - Agid, Ofer

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Although some studies have suggested that relapse may be associated with antipsychotic treatment resistance in schizophrenia, the number and quality of studies is limited. The current analysis included patients with a diagnosis of first-episode schizophrenia or schizoaffective disorder who met the following criteria: (1) referral to the First-Episode Psychosis Program between 2003 and 2013; (2) treatment with an oral second-generation antipsychotic according to a standardized treatment algorithm; (3) positive symptom remission; (4) subsequent relapse (i.e., second episode) in association with non-adherence; and (5) reintroduction of antipsychotic treatment with the same agent used to achieve response in the first episode. The following outcomes were used as an index of antipsychotic treatment response: changes in the brief psychiatric rating scale (BPRS) total and positive symptom scores and number of patients who achieved positive symptom remission and 20 and 50% response. A total of 130 patients were included in the analyses. Although all patients took the same antipsychotic in both episodes, there were significant episode-by-time interactions for all outcomes of antipsychotic treatment response over 1 year in favor of the first episode compared to the second episode (50% response rate: 48.7 vs. 10.4% at week 7; 88.2 vs. 27.8% at week 27, respectively). Although antipsychotic doses in the second episode were significantly higher than those in the first episode, results remained unchanged after adjusting for antipsychotic dose. The present findings suggest that antipsychotic treatment response is reduced or delayed in the face of relapse following effective treatment of the first episode of schizophrenia.

AB - Although some studies have suggested that relapse may be associated with antipsychotic treatment resistance in schizophrenia, the number and quality of studies is limited. The current analysis included patients with a diagnosis of first-episode schizophrenia or schizoaffective disorder who met the following criteria: (1) referral to the First-Episode Psychosis Program between 2003 and 2013; (2) treatment with an oral second-generation antipsychotic according to a standardized treatment algorithm; (3) positive symptom remission; (4) subsequent relapse (i.e., second episode) in association with non-adherence; and (5) reintroduction of antipsychotic treatment with the same agent used to achieve response in the first episode. The following outcomes were used as an index of antipsychotic treatment response: changes in the brief psychiatric rating scale (BPRS) total and positive symptom scores and number of patients who achieved positive symptom remission and 20 and 50% response. A total of 130 patients were included in the analyses. Although all patients took the same antipsychotic in both episodes, there were significant episode-by-time interactions for all outcomes of antipsychotic treatment response over 1 year in favor of the first episode compared to the second episode (50% response rate: 48.7 vs. 10.4% at week 7; 88.2 vs. 27.8% at week 27, respectively). Although antipsychotic doses in the second episode were significantly higher than those in the first episode, results remained unchanged after adjusting for antipsychotic dose. The present findings suggest that antipsychotic treatment response is reduced or delayed in the face of relapse following effective treatment of the first episode of schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=85058054718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058054718&partnerID=8YFLogxK

U2 - 10.1038/s41386-018-0278-3

DO - 10.1038/s41386-018-0278-3

M3 - Article

C2 - 30514883

AN - SCOPUS:85058054718

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

ER -